Sciatica Treatment Market Research, 2031
The global sciatica treatment market size was valued at $678 million in 2021, and is projected to reach $991.3 million by 2031, growing at a CAGR of 3.9% from 2022 to 2031. Sciatica is a condition characterized by pain that travels along the path of the sciatic nerve and leads to pain in the back, buttocks, and legs. The pain usually initiates in the lower spine, and travels through the hip and buttock and down the back of the leg to the foot. Symptoms of sciatica mainly includes the lower back pain, or tingling, numbness, or weakness in the leg. Although sciatica pain can be severe, most people find their symptoms improve with time. Sciatica can be caused due to age-related changes to the spine, obesity, occupations where one picks up heavy loads, prolonged sitting, and diabetes. Moreover, sciatica can also occur owing to the conditions such as osteoarthritis, spondylolisthesis, spinal stenosis and degenerative disk disease. It cannot be wholly treated, but the pain can be reduced using pain relieving medications such as NSAIDs, analgesics and others.
Market Dynamics
Factors that drive the growth of the sciatica treatment market include increase in incidence of chronic as well as acute sciatica, changes in human lifestyle, and increase in geriatric population. Moreover, increase in demand for over-the-counter analgesics for sciatica treatment, and increase in awareness among the population regarding treatment of sciatica are the factors that drive the growth of the acute sciatica segment.
There is an increase in geriatric population around the globe which is one of the major driving factors for the growth of the sciatica treatment market. For instance, According to World Health Organization (WHO), between 2015 and 2050, the proportion of the world's population over 60 years will nearly double from 12% to 22%. As geriatric population is more prone to chronic backpain conditions including sciatica which usually occur due to aging, there is an increase in demand for sciatica treatment medications. Thus, propels the growth of the market.
Furthermore, increase in awareness among the population in developed as well as developing countries about the sciatica condition and its available treatment options is also boosting the market growth. Moreover, increase in demand for NSAIDs and others analgesic drugs as OTC treatment option for sciatica in countries such as such as China, Brazil, and India, fuel the growth of the market.
Although various factors drive the growth of the sciatica treatment market, presence of alternate techniques for treatment of sciatica is causing hindrance to the growth of market. There are many non-surgical and surgical treatments for sciatica such as physical therapy for sciatica, chiropractic therapy and surgeries for treating sciatica such as spinal fusion surgery, foraminotomy, laminectomy and others. Thus, these factors act as a restrain to the sciatica treatment market. On the other hand, increase in investment by the key market players in developing regions and technological advances in manufacturing of pharmaceuticals is anticipated to boost the market during the forecast period.
The COVID-19 outbreak had a negative impact on growth of the global sciatica treatment market. COVID-19 pandemic was one of the biggest challenges for the healthcare system. Outbreak of the COVID-19 pandemic had led to partial or complete shutdown of production facilities, owing to prolonged lockdown in major countries such as the U.S., China, Japan, India, and Germany. This has further led to either closure or suspension of these production activities in most industrial units across the world. This also affected the manufacturing of sciatica medications to some extent. However, several developed and developing countries managed to counter the effects of the pandemic by implementing various strategies. This led to regularization of supply chain of medications and medical devices by key players after the pandemic, which will boost the market growth during the forecast period.
Segmental Overview
The sciatica treatment market is segmented by product type, treatment, distribution channel and region. By type, the market is categorized into acute sciatica, chronic sciatica and others (alternating sciatica, bilateral sciatica). On the basis of treatment, the market is segregated into non-steroidal anti-inflammatory drug (NSAIDs), steroids, antidepressants, anticonvulsants, analgesics and others (muscle relaxants, analgesics, opioids). On the basis of distribution channel, the market is categorized into hospital pharmacies, drug & retail store pharmacies and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
By Type
The chronic sciatica segment dominated the global sciatica treatment market size in 2021, and is anticipated to grow at the fastest rate during the forecast period, owing to increase in incidence of chronic sciatica, along with changes in human lifestyle and increase in cases of spine tumor and herniated disc.
By Drug Class
The non-steroidal anti-inflammatory drug (NSAIDs) segment dominated the sciatica treatment market share in 2021, and is anticipated to grow at the fastest rate during the forecast period, owing to the low cost and easy availability of NSAIDs as over the counter drug. It is also attributed to the frequent prescription of NSAIDs by the healthcare provider for people with acute and chronic sciatica.
By Distribution Channel
The drug & retail store pharmacies was the highest contributor to the sciatica treatment market size in terms of revenue, owing to its large chain of distribution networks, innovative marketing strategies, and provide better financial & debt management to the patients. On the other hand, online providers is expected to grow at the fastest rate during the forecast period, owing to time saving process and heavy discounts & offers provided by these online platforms.
By Region
The sciatica treatment market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for a major sciatica treatment market share in 2021, and is expected to maintain its dominance during the forecast period.
Presence of several major players, such as Amneal Pharmaceuticals LLC, Abbott and Johnson and Johnson and advancement in manufacturing technology of pharmaceutical formulations in the region drive the growth of the market. In addition, increase in incidences of sciatica, changes in human lifestyle and growth in geriatric population increase the demand for sciatica treatment medications in the region, which is anticipated to propel the growth of the market.
Furthermore, presence of well-established healthcare infrastructure, high purchasing power, and rise in adoption rate of sciatica relieving medications instead of surgeries, are expected to drive the sciatica treatment market growth. The presence of a large unmet healthcare needs and a favorable regulatory environment are some of the key factors that are expected to increase profitable growth of the market over the forecast period. The introduction of new products and the prevalence of beneficial government initiatives in healthcare system are some key factors contributing to its huge share.
Asia-Pacific expected to grow at the highest rate during the sciatica treatment market forecast period. The market growth in this region is attributable to presence of pharmaceutical companies in the region as well as growth in the purchasing power of populated countries, such as China and India. Moreover, rise in medicine expenditure and adoption of high-tech processing to improve the production of sciatica treatment medications, drive the growth of the market. Furthermore, the Asia-Pacific region exhibits the largest medicine supply and the largest pharmaceuticals industry with availability of raw material in abundance, which can be easily accessed by manufacturers of pharmaceutical products. This, in turn, drives the growth of the market. Asia-Pacific offers profitable sciatica treatment market opportunity for key players operating in the sciatica treatment market, thereby registering the fastest growth rate during the forecast period, owing to the growing infrastructure of industries, rising disposable incomes, as well as well-established presence of domestic companies in the region. In addition, rise in contract manufacturing organizations within the region provides great opportunity for new entrants in this region.
Competition Analysis
Competitive analysis and profiles of the major players in the sciatica treatment market, such as are provided in this report. There are some important players in the market such as Abbott, Alkem Laboratories Limited, Amneal Pharmaceuticals LLC., Aurobindo Pharma, Johnson and Johnson, Sinfonia Biotherapeutics, Sorrento Therapeutics, Inc, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Limited and Zydus Group. SpineThera, Inc., Vita Lifesciences LLC and others are some of the major players in this market. Major players have adopted product launch, product development, clinical trials and branding as key developmental strategies to improve the product portfolio of the sciatica market.
Some Examples Of Product Launches In The Market
In March 2021, Abbott announced the launch of its new Brufen Power spray, a unique double-strength formulation of proven pain-relieving active ingredient diclofenac, delivered with a unique one-shot spray. It is developed using one shot technology and a 2% double-strength diclofenac formula, ensures low wastage and powerful, targeted pain relief.
In October 2019, Sun Pharmaceutical Industries Ltd. announced the launch of Drizalma Sprinkle (duloxetine delayed-release capsules) in the U.S. for oral use. Drizalma Sprinkle is a serotonin and norepinephrine reuptake inhibitor (SNRI) designed for the treatment of various neuro-psychiatric and pain disorders. The U.S. Food and Drug Administration (FDA) approved Drizalma Sprinkle on July 19, 2019.
In August 2021, Alkem Laboratories Ltd. announced the launch of Ibuprofen and Famotidine Tablets in the U.S., following an approval from the U.S. Food and Drug Administration (US FDA).
Clinical trials
In May 2022, Sorrento Therapeutics announced the highly positive results of pivotal Phase 3 SEMDEXATM in sciatica patients following an epidural injection and presented the data at the American Society of Interventional Pain 2022 annual meeting.
In December 2021, Sorrento Therapeutics announced highly significant positive results from its Phase 3 SP-102 (SEMDEXA) Pivotal Trial C.L.E.A.R Program for its injectable, dexamethasone sodium phosphate viscous gel product for the treatment of lumbosacral radicular pain.
Geographical Expansion
In April 2022, Sorrento Therapeutics announced the expansion of its direct distribution network to national and regional wholesalers and pharmacies through Cardinal 3PL which will act as a third-party logistics function for Scilex.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the sciatica treatment market analysis from 2021 to 2031 to identify the prevailing sciatica treatment market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the sciatica treatment industry segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global sciatica treatment market trends, key players, market segments, application areas, and market growth strategies.
Sciatica Treatment Market Report Highlights
| Aspects | Details |
 Market Size By 2031 | USD 991.3 million |
 Growth Rate | CAGR of 3.9% |
 Forecast period | 2021 - 2031 |
 Report Pages | 241 |
 By Type |
|
 By Drug class |
|
 By Distribution channel |
|
 By Region |
|
 Key Market Players | Johnson and Johnson, Amneal Pharmaceuticals LLC, Aurobindo Pharma, Alkem Laboratories Ltd, Sorrento Therapeutics, Inc, Sinfonia Biotherapeutics, Zydus Lifesciences Limited, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Ltd., Abbott Laboratories |
Analyst Review
This section provides various opinions of top-level CXOs in the global sciatica treatment market. According to the insights of CXOs, the increase in demand for efficient and high-quality medications for the treatment of sciatica is expected to offer profitable opportunities for the expansion of the sciatica treatment market. Also, increase in adoption of NSAIDs as medication for treatment of sciatica by healthcare providers is boosting the growth of the market. Moreover, technological advancements in manufacturing and development of formulations have increased the production capacity as well as the efficacy and quality of the medication, which is driving the growth of the market.
CXOs further added that increase in incidence of sciatica in the population of developed as well as developing regions has largely contributed toward the market revenue in 2021, and is expected to maintain this trend throughout the forecast period. Also, increase in awareness around the globe regarding sciatica disease and its treatment options, significantly contributes towards the revenue generation. In addition, increase in prevalence of conditions such as herniated disc, bone spurs, or rarely the tumor increase the incidence of sciatica, which contributes to the growth of the sciatica treatment market.
Furthermore, North America is expected to witness highest growth, in terms of revenue, owing to increase in awareness among the people regarding management of various disease conditions and rise in government initiatives for offering effective patient care, lead to the growth of the market. However, Asia-Pacific is anticipated to witness notable growth, owing to increase in investments for manufacturing of pharmaceutical products in the emerging economies such as India and China
Major factors that drive the growth of the sciatica treatment market include increase in incidence of sciatica, surge in R&D activities for developing novel therapeutics for sciatica and rise in awareness among the people regarding sciatica and its treatments.
Chronic sciatica is the leading type in the sciatica treatment market.
North America is the largest regional market for sciatica treatment.
Abbott, Alkem Laboratories Limited, Amneal Pharmaceuticals LLC., Aurobindo Pharma, Johnson & Johnson, Sinfonia Biotherapeutics, Sorrento Therapeutics, Inc, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Limited and Zydus Group., are the top companies to hold the market share in sciatica treatment.
The sciatica treatment market valued for $678.02 million in 2021 and is estimated to reach $991.26 million by 2031, exhibiting a CAGR of 3.9% from 2022 to 2031.
2021 is the base year of sciatica treatment market.
2022-2031 is the forecast year of sciatica treatment market.
Loading Table Of Content...
